Biotech company closes heavily oversubscribed financing round

More than 70 investors participated in biotech company Synklino's financing round with proceeds going to the drug development for organ transplant patients infected with the herpesvirus cytomegalovirus (CMV).

Thomas N. Kledal, co-founder and CEO at Synklione (to the right) and John Haurum, chairman of the board of Synklino. | Photo: Synklino / PR

Finding the necessary capital to continue operations has been smooth sailing for biotech company Synklino, which reported on Monday that a financing round has concluded, bringing in DKK 106m (USD 16.2m).

Synklino had only expected a third of that figure, but the investment round was popular among old and new investors alike. This included the existing backers, Nordic funds Vækstfonden and Eir Ventures, as well as current management and board members, in addition to 70 new investors, comprising both private investors and interested family offices, and new institutional investors such as Strategic Investments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs